The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Implementation of the sFlt‐1/PlGF ratio for prediction and diagnosis of pre‐eclampsia in singleton pregnancy: implications for clinical practice
Open accessAbstract
Pre-eclampsia (PE) is a leading cause of maternal and fetal/neonatal morbidity and mortality worldwide. Clinical diagnosis and definition of PE is commonly based on the measurement of non-specific signs and symptoms, principally hypertension and proteinuria1–3. However, due to the recognition that measurement of proteinuria is prone to inaccuracies and the fact that PE complications often occur before proteinuria becomes significant, most recent guidelines also support the diagnosis of PE on the basis of hypertension and signs of maternal organ dysfunction other than proteinuria3–5. Furthermore, the clinical presentation and course of PE is variable, ranging from severe and rapidly progressing early-onset PE, necessitating preterm delivery, to late-onset PE at term. There may be associated intrauterine growth restriction (IUGR), further increasing neonatal morbidity and mortality. These features suggest that the classical standards for the diagnosis of PE are not sufficient to encompass the complexity of the syndrome. Undoubtedly, proper management of pregnant women at high risk for PE necessitates early and reliable detection and intensified monitoring, with referral to specialized perinatal care centers, to reduce substantially maternal, fetal and neonatal morbidity6,7. In the decade since Maynard et al.8 reported that excessive placental production of soluble fms-like tyrosine kinase receptor-1 (sFlt-1), an antagonist of vascular endothelial growth factor and placental growth factor (PlGF), contributes to the pathogenesis of PE, extensive research has been published demonstrating the usefulness of angiogenic markers in both diagnosis and the subsequent prediction and management of PE and placenta-related disorders. Various reports have demonstrated that disturbances in angiogenic and antiangiogenic factors are implicated in the pathogenesis of PE and have possible relevance in the diagnosis and prognosis of the disease. Increased serum levels of sFlt-1 and decreased levels of PlGF, thereby resulting in an increased sFlt-1/PlGF ratio, can be detected in the second half of pregnancy in women diagnosed to have not only PE but also IUGR or stillbirth, i.e. placenta-related disorders. These alterations are more pronounced in early-onset rather than late-onset disease and are associated with severity of the clinical disorder. Moreover, the disturbances in angiogenic factors are reported to be detectable prior to the onset of clinical symptoms (disease), thereby allowing discrimination of women with normal pregnancies from those at high risk for developing pregnancy complications, primarily PE9–30. Plasma concentrations of angiogenic/antiangiogenic factors are of prognostic value in obstetric triage: similar to the progressively worsening clinical course observed in women with early-onset PE, changes in the angiogenic profile leading to a more antiangiogenic state can be found. Current definitions of PE are poor in predicting PE-related adverse outcomes. A diagnosis of PE based on blood pressure and proteinuria has a positive predictive value of approximately 30% for predicting PE-related adverse outcomes31. Estimation of the sFlt-1/PlGF ratio allows identification of women at high risk for imminent delivery and adverse maternal and neonatal outcome23,30,32–35. Moreover, it has also been shown that the time-dependent slope of the sFlt-1/PlGF ratio between repeated measurements is predictive for pregnancy outcome and the risk of developing PE, and repeated measurements have been suggested36. However, the ‘optimal’ time interval for a follow-up test remains unclear. Finally, high values are closely related to the need to deliver immediately22,23,37. Additionally, in normal and complicated pregnancies, angiogenic factors are correlated with Doppler ultrasound parameters, mainly uterine artery (UtA) indices38–42. Combining the sFlt-1/PlGF ratio with UtA Doppler ultrasound, at the time of diagnosis of early-onset PE, has prognostic value mainly for perinatal complications, being limited for the prediction of maternal complications37,43. The additional measurement of the sFlt-1/PlGF ratio has been shown to improve the sensitivity and specificity of Doppler measurement in predicting PE44–48, supporting its implementation in screening algorithms. Whereas studies on the predictive efficacy of the sFlt-1/PlGF ratio in the first trimester have yielded contradictory results49, reports on the use of this marker as an aid in prediction from the mid trimester onwards have led to its suggested use as a screening tool, especially for identifying all women developing PE and requiring delivery within the subsequent 4 weeks50–52. This short review of the literature highlights that measurement of the sFlt-1/PlGF ratio has the potential to become an additional tool in the management of PE, particularly as automated tests that allow rapid and easy measurement of these markers are now widely available. Nevertheless, although these markers were incorporated recently into the German guidelines53, no formal recommendation regarding how to use sFlt-1, PlGF or the sFlt-1/PlGF ratio has been established in any official protocol. The purpose of this paper is to answer questions that are frequently asked around the use of the sFlt-1/PlGF ratio in the diagnosis and prediction of PE and regarding the implications for clinical practice, in particular, ‘When?’ and ‘In which women?’ should the sFlt-1/PlGF ratio be measured and, ‘What should be done with the results?’, and to provide guidance to educate physicians on the use of the sFlt-1/PlGF ratio in clinical practice. To achieve this, international experts in the use of angiogenic markers have strived to develop a consensus statement on the clinical use of the sFlt-1/PlGF ratio and the consequential management in pregnant women with suspected PE or at a high risk of developing PE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maynard, S. E., Min, J.-Y., Merchan, J., Lim, K.-H., Li, J., Mondal, S., Libermann, T. A., Morgan, J. P., Sellke, F. W., Stillman, I. E., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17189 · Cited by 4,101
(2013) · doi:10.1097/01.aog.0000437382.03963.88 · Cited by 3,961
Circulating angiogenic factors and the risk of preeclampsia
Levine, R. J., Maynard, S. E., Qian, C., Lim, K.-H., England, L. J., Yu, K. F., Schisterman, E. F., Thadhani, R., Sachs, B. P., Epstein, F. H., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031884 · Cited by 3,720
Circulating angiogenic factors and the risk of preeclampsia*
(2004) · Obstetrics & Gynecology · doi:10.1097/00006250-200405000-00028 · Cited by 2,615
Onuegbu, A. J., Olisekodiaka, J. M., Udo, J. U., Umeononihu, O., Amah, U. K., Okwara, J. E., & Atuegbu, C. (2015) · Medical Principles and Practice · doi:10.1159/000381778 · Cited by 2,044
Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia
Levine, R. J., Lam, C., Qian, C., Yu, K. F., Maynard, S. E., Sachs, B. P., Sibai, B. M., Epstein, F. H., Romero, R., Thadhani, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055352 · Cited by 1,802
Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia
Zeisler, H., Llurba, E., Chantraine, F., Vatish, M., Staff, A. C., Sennström, M., Olovsson, M., Brennecke, S. P., Stepan, H., Allegranza, D., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1414838 · Cited by 1,783
Self-citationTranquilli, A. L., Dekker, G., Magee, L., Roberts, J., Sibai, B. M., Steyn, W., Zeeman, G. G., & Brown, M. A. (2014) · Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health · doi:10.1016/j.preghy.2014.02.001 · Cited by 1,417
Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia
(2006) · New England Journal of Medicine · doi:10.1056/nejmx060063 · Cited by 1,235
Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy: Executive Summary
Magee, L. A., Pels, A., Helewa, M., Rey, E., von Dadelszen, P., Magee, L. A., Audibert, F., Bujold, E., Côté, A.-M., Douglas, M. J., et al. (2014) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(15)30588-0 · Cited by 683
Romero, R., Nien, J. K., Espinoza, J., Todem, D., Fu, W., Chung, H., Kusanovic, J. P., Gotsch, F., Erez, O., Mazaki-Tovi, S., et al. (2008) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767050701830480 · Cited by 675
Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia
Rana, S., Powe, C. E., Salahuddin, S., Verlohren, S., Perschel, F. H., Levine, R. J., Lim, K.-H., Wenger, J. B., Thadhani, R., & Karumanchi, S. A. (2012) · Circulation · doi:10.1161/circulationaha.111.054361 · Cited by 668
Verlohren, S., Herraiz, I., Lapaire, O., Schlembach, D., Moertl, M., Zeisler, H., Calda, P., Holzgreve, W., Galindo, A., Engels, T., et al. (2012) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2011.07.037 · Cited by 448
Self-citationAn automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia
Verlohren, S., Galindo, A., Schlembach, D., Zeisler, H., Herraiz, I., Moertl, M. G., Pape, J., Dudenhausen, J. W., Denk, B., & Stepan, H. (2010) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2009.09.016 · Cited by 428
Self-citationVerlohren, S., Herraiz, I., Lapaire, O., Schlembach, D., Zeisler, H., Calda, P., Sabria, J., Markfeld-Erol, F., Galindo, A., Schoofs, K., et al. (2014) · Hypertension · doi:10.1161/hypertensionaha.113.01787 · Cited by 372
Self-citationChaiworapongsa, T., Romero, R., Kim, Y. M., Kim, G. J., Kim, M. R., Espinoza, J., Bujold, E., Gonçalves, L., Gomez, R., Edwin, S., et al. (2005) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767050400028816 · Cited by 359
Kusanovic, J. P., Romero, R., Chaiworapongsa, T., Erez, O., Mittal, P., Vaisbuch, E., Mazaki-Tovi, S., Gotsch, F., Edwin, S. S., Gomez, R., et al. (2009) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767050902994754 · Cited by 275
Espinoza, J., Romero, R., Nien, J. K., Gomez, R., Kusanovic, J. P., Gonçalves, L. F., Medina, L., Edwin, S., Hassan, S., Carstens, M., et al. (2007) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2006.11.002 · Cited by 266
Stepan, H., Unversucht, A., Wessel, N., & Faber, R. (2007) · Hypertension · doi:10.1161/01.hyp.0000258404.21552.a3 · Cited by 237
Self-citationPrediction of adverse outcomes by common definitions of hypertension in pregnancy
Zhang, J. (2001) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(00)01125-x · Cited by 188
Wikström, A.-K., Larsson, A., Eriksson, U. J., Nash, P., Nordén-Lindeberg, S., & Olovsson, M. (2007) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000264552.85436.a1 · Cited by 188
Angiogenic factors for the prediction of preeclampsia in high-risk women
Moore Simas, T. A., Crawford, S. L., Solitro, M. J., Frost, S. C., Meyer, B. A., & Maynard, S. E. (2007) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2007.06.030 · Cited by 185
Wallner, W., Sengenberger, R., Strick, R., Strissel, P. L., Meurer, B., Beckmann, M. W., & Schlembach, D. (2007) · Clinical Science · doi:10.1042/cs20060161 · Cited by 175
Self-citationSoto, E., Romero, R. J., Kusanovic, J. P., Oggè, G., Hussein, Y., Yeo, L., Hassan, S. S., Kim, C. J., & Chaiworapongsa, T. (2011) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2011.591461 · Cited by 160
Zeisler, H., Llurba, E., Chantraine, F., Vatish, M., Staff, A. C., Sennström, M., Olovsson, M. H., Brennecke, S. P., Stepan, H., Allegranza, D., et al. (2018) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.19178 · Cited by 150
Self-citationChaiworapongsa, T., Romero, R. J., Korzeniewski, S. J., Kusanovic, J. P., Soto, E., Lam, J., Dong, Z., Than, N. G., Yeo, L., Hernandez‐Andrade, E. A., et al. (2013) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2013.01.016 · Cited by 146
Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia
Verlohren, S., Stepan, H., & Dechend, R. (2011) · Clinical Science · doi:10.1042/cs20110097 · Cited by 141
Self-citationChaiworapongsa, T., Romero, R. J., Savasan, Z. A., Kusanovic, J. P., Oggè, G., Soto, E., Dong, Z., Tarca, A. L., Bhatti, G., & Hassan, S. S. (2011) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2011.589932 · Cited by 139
Chaiworapongsa, T., Espinoza, J., Gotsch, F., Kim, Y. M., Kim, G. J., Gonçalves, L. F., Edwin, S. S., Kusanovic, J. P., Erez, O., Than, N. G., et al. (2008) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767050701832833 · Cited by 116
Schiettecatte, J., Russcher, H., Anckaert, E., Mees, M., Leeser, B., Tirelli, A. S., Fiedler, M., Luthe, H., Denk, B., & Smitz, J. E. J. (2010) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2010.02.010 · Cited by 110
Schlembach, D., Wallner, W., Sengenberger, R., Stiegler, E., Mörtl, M., Beckmann, M., & Lang, U. E. (2007) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.3930 · Cited by 103
Self-citationHerraı̀z, I., Dröge, L. A., Gómez‐Montes, E., Henrich, W., Galindo, A., & Verlohren, S. (2014) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000000367 · Cited by 98
Self-citationOhkuchi, A., Hirashima, C., Suzuki, H., Takahashi, K., Yoshida, M., Matsubara, S., & Suzuki, M. (2010) · Hypertension Research · doi:10.1038/hr.2010.15 · Cited by 91
Perinatal regionalization and neonatal mortality in North Carolina, 1968-1994
Bode, M. M., O’Shea, T. M., Metzguer, K., & Stiles, A. D. (2001) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2001.114484 · Cited by 90
Zeisler, H., Llurba, E., Chantraine, F., Vatish, M., Staff, A. C., Sennström, M., Olovsson, M. H., Brennecke, S. P., Stepan, H., Allegranza, D., et al. (2016) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000001525 · Cited by 90
Self-citationChaiworapongsa, T., Romero, R. J., Korzeniewski, S. J., Cortez, J. M., Pappas, A., Tarca, A. L., Chaemsaithong, P., Dong, Z., Yeo, L., & Hassan, S. S. (2013) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2013.806905 · Cited by 88
Lobmaier, S. M., Figueras, F., Mercade, I., Perelló, M. F., Peguero, A., Crovetto, F., Ortiz, J. U., Crispi, F., & Gratacós, E. (2013) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.13246 · Cited by 82
The course of angiogenic factors in early- vs. late-onset preeclampsia and HELLP syndrome
Schaarschmidt, W., Rana, S., & Stepan, H. (2013) · Journal of Perinatal Medicine · doi:10.1515/jpm-2012-0248 · Cited by 78
Self-citationHund, M., Allegranza, D., Schoedl, M., Dilba, P., Verhagen-Kamerbeek, W. D. J., & Stepan, H. (2014) · BMC Pregnancy and Childbirth · doi:10.1186/1471-2393-14-324 · Cited by 77
Self-citationRomero, R. J., Chaiworapongsa, T., Erez, O., Tarca, A. L., Gervasi, M. T., Kusanovic, J. P., Mittal, P., Oggè, G., Vaisbuch, E., Mazaki‐Tovi, S., et al. (2010) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767051003681121 · Cited by 70
Lai, J., Garcia-Tizon Larroca, S., Peeva, G., Poon, L. C., Wright, D., & Nicolaides, K. H. (2014) · Fetal Diagnosis and Therapy · doi:10.1159/000359968 · Cited by 63
Uterine artery Doppler and sFlt ‐1/ PlGF ratio: prognostic value in early‐onset pre‐eclampsia
Gómez‐Arriaga, P. I., Herraı̀z, I., López-Jiménez, E. A., Escribano, D., Denk, B., & Galindo, A. (2013) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.13224 · Cited by 59
Self-citationPinheiro, C. C., Rayol, P., Gozzani, L., dos Reis, L. M., Zampieri, G., Dias, C. B., & Woronik, V. (2014) · Prenatal Diagnosis · doi:10.1002/pd.4432 · Cited by 56
Leaños‐Miranda, A., Campos-Galicia, I., Isordia‐Salas, I., Rivera‐Leaños, R., Romero-Arauz, J. F., Méndez, J. A. A., & Ulloa‐Aguirre, A. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e328357c0c9 · Cited by 54
Alahakoon, T. I., Zhang, W., Trudinger, B., & Lee, V. W. (2014) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2014.880882 · Cited by 45
Larroca, S. G., Tayyar, A., Poon, L. C., Wright, D. E., & Nicolaides, K. H. (2014) · Fetal Diagnosis and Therapy · doi:10.1159/000362518 · Cited by 39
Uterine artery Doppler and sFlt ‐1/ PlGF ratio: usefulness in diagnosis of pre‐eclampsia
Gómez‐Arriaga, P. I., Herraı̀z, I., López-Jiménez, E. A., Gómez‐Montes, E., Denk, B., & Galindo, A. (2013) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.12400 · Cited by 36
Self-citationHolmes, V. A., Young, I. S., Patterson, C., Maresh, M., Pearson, D. W. M., Walker, J. D., McCance, D. R., & for the Diabetes and Preeclampsia Intervention Trial (DAPIT) Study Group (2013) · Diabetes Care · doi:10.2337/dc13-0944 · Cited by 34
Stubert, J., Ullmann, S., Bolz, M., Külz, T., Dieterich, M., Richter, D.-U., & Reimer, T. (2014) · BMC Pregnancy and Childbirth · doi:10.1186/1471-2393-14-292 · Cited by 33
Hassan, M. F., Rund, N. M. A., & Salama, A. H. (2013) · Obstetrics and Gynecology International · doi:10.1155/2013/202346 · Cited by 29
Forest, J., Thériault, S., Massé, J., Bujold, E., & Giguère, Y. (2014) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2013-0955 · Cited by 27
Diguisto, C., Gouge, A. L., Piver, É., Giraudeau, B., & Perrotin, F. (2013) · Prenatal Diagnosis · doi:10.1002/pd.4198 · Cited by 23
Kulmala, L., & Phupong, V. (2014) · Hypertension Research · doi:10.1038/hr.2014.27 · Cited by 17
Hirashima, C., Ohkuchi, A., Takahashi, K., Suzuki, H., Matsubara, S., & Suzuki, M. (2014) · Hypertension Research · doi:10.1038/hr.2014.31 · Cited by 17
Petzold, K., Jank, A., Faber, R., & Stepan, H. (2010) · Hypertension in Pregnancy · doi:10.3109/10641955.2010.506234 · Cited by 9
Self-citation
Cited by
Rana (2019) · doi:10.1161/circresaha.118.313276 · Cited by 2,095
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Pre‐eclampsia‐like syndrome induced by severe COVID‐19: a prospective observational study
Mendoza, M., Garcia‐Ruiz, I., Maiz, N., Rodo, C., Garcia‐Manau, P., Serrano, B., Lopez‐Martinez, R., Balcells, J., Fernandez‐Hidalgo, N., Carreras, E., et al. (2020) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.16339 · Cited by 370
Rana, S., Burke, S. D., & Karumanchi, S. A. (2022) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2020.10.022 · Cited by 335
The T helper type 17/regulatory T cell paradigm in pregnancy
Figueiredo, A. S., & Schumacher, A. (2016) · Immunology · doi:10.1111/imm.12595 · Cited by 283
Metadata
- Authors
- Stepan, H., Herraiz, I., Schlembach, D., Verlohren, S., Brennecke, S., Chantraine, F., Klein, E., Lapaire, O., Llurba, E., Ramoni, A., Vatish, M., Wertaschnigg, D., & Galindo, A.
- Venue
- Ultrasound in Obstetrics & Gynecology
- Publisher
- Wiley
- Published
- 2015-03
- Volume
- 45
- Issue
- 3
- Pages
- 241-246
- ISSN
- 0960-7692 (ISSN-L)
- 1469-0705
- OpenAlex
- W2079661513
- Cited by
- 264
- References
- 55
- FWCI
- 25.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.